Investors

News Releases

Oct 26, 2020

Evofem Biosciences to Participate in Virtual Investor KOL Roundtable

- Live moderated video webcast discussion with members of Evofem management and Key Opinion Leader Patty Cason, RN, MS, FNP-BC, on Thursday, October 29th at 2:00 p.m. ET -
Oct 20, 2020

Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea
Oct 15, 2020

Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital
Oct 7, 2020

Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society Meetings
Sep 16, 2020

Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference
- Photos 1
Sep 14, 2020

Evofem Biosciences to Present Data at the 2020 STD Prevention Virtual Conference from Phase 2b Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women

- Company plans to initiate Phase 3 STI trial by the end of 2020 -
Sep 8, 2020

Evofem Biosciences Announces U.S. Commercial Launch of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal, On-Demand Prescription Contraceptive Vaginal Gel

- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -
Aug 31, 2020

Evofem Biosciences to Participate in Four Upcoming Investor Conferences
Aug 21, 2020

Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2020

Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -

Show per page